Search results for "Vitamin"

showing 10 items of 931 documents

Ibandronic acid subsequent to raloxifene: Effect on bone metabolism and on cardiovascular risk factors

2015

s / Maturitas 81 (2015) 144–190 161 Materials andmethods: This randomized double-blind clinical trialwas carried out inAhvaz (Iran) fromAugust toDecember 2010. Forty postmenopausal women with symptoms of vaginal atrophy were randomly allocated to two groups to take vaginal suppositories of either 5mg hyaluronic acid sodium salt (n=20) or 1mg vitamin E (n=20) for 8 weeks. The symptoms of vaginal atrophy were evaluated by a self-assessed 4-point scale and the composite score was determined as none, mild, moderate, and severe in four periods. Results: The results showed that the symptoms were relieved significantly in both groups (P<0.001). The relief of symptomswas significantly superior in t…

medicine.medical_specialtymedicine.drug_classbusiness.industryVitamin Emedicine.medical_treatmentCardiovascular risk factorsObstetrics and Gynecologymedicine.diseaseGastroenterologyIbandronic acidGeneral Biochemistry Genetics and Molecular BiologyBone remodelingchemistry.chemical_compoundEndocrinologychemistryEstrogenInternal medicineHyaluronic acidmedicineRaloxifeneVaginal atrophybusinessmedicine.drugMaturitas
researchProduct

Antithrombotic treatment and outcomes of splanchnic vein thrombosis in an international prospective registry: Results of 2-year follow-up

2014

Abstract Background: Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT). We aimed to assess incidence rates of bleeding, recurrence, and mortality in a large prospective cohort of SVT patients after a 2-year follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Information was gathered on baseline characteristics, risk factors and therapeutic strategies. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis, and mortality) during follow-up were collected and reviewed by a Central Adjudication Committee. Major bleeding was de…

medicine.medical_specialtymedicine.drug_classliver cirrhosisImmunologyanticoagulant agentBiochemistrymaleInternal medicinedeathMedicinefollow upartery thrombosishumanRisk factorProspective cohort studythrombosisriskregisteranticoagulant therapybusiness.industryhematologyIncidence (epidemiology)pathogenesisAnticoagulantCell Biologymedicine.diseasebleedingThrombosismortalitySurgeryVenous thrombosissocietySplanchnic vein thrombosisvein thrombosisrisk factorsolidincidenceantivitamin KpatientbusinessAmericanFibrinolytic agentneoplasmhospitalizationportal vein
researchProduct

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

2020

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Aims To provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of acute ischemic stroke or intracranial hemorrhage. Methods Retrospective data collected from German neurological/neurosurgical departments ad…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizinAntibodies Monoclonal HumanizedAntithrombinsBrain IschemiaDabigatranGermanyInternal medicinemedicineHumansThrombolytic Therapyddc:610Ischemic StrokeRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabAtrial fibrillationThrombolysisVitamin K antagonistmedicine.diseaseDabigatranStrokeNeurologyCardiologybusinessIntracranial Hemorrhagesmedicine.drugInternational Journal of Stroke
researchProduct

Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women

2018

To evaluate the vitamin D status of postmenopausal women with early estrogen-receptor-positive breast cancer and to compare it with that of healthy postmenopausal women from the same Mediterranean region. STUDY DESIGN AND OUTCOME MEASURES: Data from 691 breast cancer (BC) patients in the B-ABLE cohort were analyzed after recent cancer intervention (recent-BC) or after a minimum of two years since this intervention (long-term-BC). Patients were also stratified by previous chemotherapy exposure (ChT+ and ChT-). Plasma levels of 25-hydroxyvitamin D [25(OH)D] (25(OH)D) were compared with data from 294 healthy women (non-BC) by linear regression to estimate β-coefficients using non-BC participan…

medicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsGastroenterologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineVitamin D and neurologyHumansChemotherapyMedicineIn patient030212 general & internal medicineVitamin DAgedChemotherapyMediterranean Regionbusiness.industryHealthy populationConfoundingB-ABLE cohort studyObstetrics and GynecologyMiddle AgedVitamin D Deficiencymedicine.diseasePostmenopause030220 oncology & carcinogenesisCohortFemalebusinessBody mass indexMaturitas
researchProduct

Beneficial Effects of Leucine Supplementation on Criteria for Sarcopenia: A Systematic Review

2019

Objective: Treating sarcopenia remains a challenge, and nutritional interventions present promising approaches. We summarize the effects of leucine supplementation in treating older individuals with sarcopenia associated with aging or to specific disorders, and we focus on the effect of leucine supplementation on various sarcopenia criteria, e.g., muscular strength, lean mass, and physical performance. Methods: A literature search for articles related to this topic was performed on the relevant databases, e.g., the PubMed/Medline, Embase, EBSCO, Cochrane, Lilacs, and Dialnet. The identified articles were reviewed according to Preferred Reporting Items for Systematic reviews and meta-analyse…

medicine.medical_specialtymedicine.medical_treatmentMEDLINElcsh:TX341-641030209 endocrinology & metabolismReviewPhysical strengthelderlysarcopenia03 medical and health sciences0302 clinical medicineLeucineInternal medicineVitamin D and neurologyHumansMedicine030212 general & internal medicineNutrition and DieteticsRehabilitationbusiness.industrymedicine.diseaseSystematic reviewSarcopeniaDietary Supplementsmuscular massLean body massLeucinebusinesslcsh:Nutrition. Foods and food supplymuscular strengthFood ScienceNutrients
researchProduct

Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol suppl…

2007

Objective— Phospholipid transfer protein (PLTP) is a multifunctional, extracellular lipid transport protein that plays a major role in lipoprotein metabolism and atherosclerosis. Recent in vivo studies suggested that unlike systemic PLTP, macrophage-derived PLTP would be antiatherogenic. The present study aimed at characterizing the atheroprotective properties of macrophage-derived PLTP. Methods and Results— Peritoneal macrophages were isolated from PLTP-deficient and wild-type mice and their biochemical characteristics were compared. It is shown that macrophages isolated from PLTP-deficient mice have increased basal cholesterol content and accumulate more cholesterol in the presence of LD…

medicine.medical_specialtymedicine.medical_treatmentalpha-TocopherolOxidative phosphorylationBiologychemistry.chemical_compoundMiceIn vivoPhospholipid transfer proteinInternal medicineMalondialdehydeExtracellularmedicineAnimalsTocopherolPhospholipid Transfer ProteinsMice KnockoutCholesterolVitamin EVitaminsLipoproteins LDLEndocrinologyCholesterolchemistryBiochemistryDietary SupplementsMacrophages Peritoneallipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinealpha-TocopherolArteriosclerosis, thrombosis, and vascular biology
researchProduct

Specialized Management of Oral Anticoagulation Therapy Improves Outcome in Patients with Chronic Renal Insufficiency

2020

Oral anticoagulation (OAC) is effective at preventing and treating thromboses and thromboembolism in patients with normal renal function. We aimed to research the impact of severe renal failure (RF) on patient outcome and to determine the potential benefit of caring for these patients in a specialized coagulation service (CS). A total of 1516 usual medical care patients and 756 CS-managed patients of the thrombEVAL multicenter (21 centers), prospective, cohort study (NCT01809015) were analyzed in a 3-year follow-up. Patients with RF (serum creatinine &gt

medicine.medical_specialtymedicine.medical_treatmentlcsh:MedicineRenal function030204 cardiovascular system & hematologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineIn patient030212 general & internal medicineRenal replacement therapyAdverse effectcoagulation serviceOral anticoagulationoral anticoagulationCreatininevitamin k-antagonistsbusiness.industrylcsh:RHazard ratioGeneral Medicineadverse eventschemistrybusinesschronic kidney diseaseCohort studyJournal of Clinical Medicine
researchProduct

Pulmonary Embolism: Contemporary Medical Management and Future Perspectives

2018

Pulmonary embolism (PE) contributes substantially to the global disease burden. A key determinant of early adverse outcomes is the presence (and severity) of right ventricular dysfunction. Consequently, risk-adapted management strategies continue to evolve, tailoring acute treatment to the patients' clinical presentation, hemodynamic status, imaging and biochemical markers, and comorbidity. For subjects with hemodynamic instability or 'high-risk' PE, immediate systemic reperfusion treatment with intravenous thrombolysis is indicated; emerging approaches such as catheter-directed pharmacomechanical reperfusion might help to minimize the bleeding risk. Currently, direct, non-vitamin K-depende…

medicine.medical_specialtythrombolysispulmonary embolismmedicine.medical_treatmentvenous thromboembolismHemodynamicsReview Articlerisk stratification030204 cardiovascular system & hematologyVitamin kdirect oral anticoagulants03 medical and health sciences0302 clinical medicinemedicine030212 general & internal medicineIntensive care medicineDisease burdenbusiness.industryGeneral MedicineThrombolysismedicine.diseaseComorbidityRight ventricular dysfunctionReview articlePulmonary embolismright ventricular dysfunctionbusinessAnnals of Vascular Diseases
researchProduct

Klotho and vitamin D in multiple sclerosis: an Italian study

2019

Introduction Low vitamin D levels have been recognised as an important risk factor for autoimmune diseases, including multiple sclerosis (MS). MS is a multifactorial disease, the pathogenesis of which contributes both to genetic and environmental factors. Polymorphisms in genes codifying molecules involved in vitamin D homeostasis have been associated with hypovitaminosis D. However, the influence of polymorphisms of Klotho, which codify a protein with a pivotal role in vitamin D metabolism, have never been investigated. The aim of this study was to evaluate the association among genetic variants of Klotho, namely rs1207568 and rs9536314, serum 25(OH)D3 levels, and multiple sclerosis (both …

medicine.medical_specialtyvitamin D Klotho genetic multiple sclerosisbusiness.industryMultiple sclerosisSingle-nucleotide polymorphismvitamin DGeneral Medicinemedicine.diseasemultiple sclerosisKlotho03 medical and health sciences0302 clinical medicineEndocrinologyClinical ResearchInternal medicineGenotypeGenetic predispositionVitamin D and neurologyMedicine030212 general & internal medicineAllelegeneticbusinessKlothoGenotyping
researchProduct

MYOCARDIAL POTENCY OF AQUEOUS EXTRACT OF HARUNGANA MADAGASCARIENSIS STEM BARK AGAINST ISOPROTERENOL-INDUCED MYOCARDIAL DAMAGE IN RATS

2018

Objectives: The present study was undertaken to evaluate the effects of Harungana madagascariensis on electrocardiographical, biochemical and histopathological changes in isoproterenol (ISO)-induced myocardial infarction in rats. Methods: Male Wistar albino rats were randomly divided and treated with the aqueous extract of Harungana madagascariensis stem bark (AEHM, 200 and 400 mg/kg per os), or normal saline or vitamin E for 7 days with concomitant administration of ISO (85 mg/kg, subcutaneously) on 8th and 9th days, at 24 h interval. Results: The ISO injections to the rats caused cardiac dysfunction evidenced by a marked (P<0.01) elevation in ST-segment, a reduction in R wave amplitude (P…

medicine.medical_treatmentCardiac marker01 natural sciencesLipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineLactate dehydrogenasemedicineHarungana[CHIM]Chemical SciencesPotencyComputingMilieux_MISCELLANEOUSbiologyTraditional medicinebusiness.industryVitamin E[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesMalondialdehydebiology.organism_classification030205 complementary & alternative medicine0104 chemical sciences3. Good health010404 medicinal & biomolecular chemistrychemistryFlacourtia indicabusinessUniversal Journal of Pharmaceutical Research
researchProduct